20628389

Source:http://linkedlifedata.com/resource/pubmed/id/20628389

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0027651, umls-concept:C0030705, umls-concept:C0140080, umls-concept:C0205179, umls-concept:C0205195, umls-concept:C0205208, umls-concept:C0205390, umls-concept:C0246415, umls-concept:C1274040, umls-concept:C1707143, umls-concept:C1999216, umls-concept:C2603343, umls-concept:C2713009
pubmed:issue	3
pubmed:dateCreated	2010-7-27
pubmed:abstractText	This phase Ib trial assessed safety, tolerability, and maximum tolerated dose (MTD) of figitumumab (CP-751,871), a fully human monoclonal antibody targeting the insulin-like growth factor type 1 receptor (IGF-IR), in combination with docetaxel.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-11410521, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-12193537, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-12473575, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-12581018, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-14666684, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-15501967, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-15650828, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-15756033, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-15829155, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-16778368, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-16844299, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-16931767, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-17575225, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-17908976, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-18474873, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-18641009, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-18829513, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-19029956, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-19380445, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-19671737, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-19786654, http://linkedlifedata.com/resource/pubmed/commentcorrection/20628389-9593409
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0370635
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/docetaxel, http://linkedlifedata.com/resource/pubmed/chemical/figitumumab
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1532-1827
pubmed:author	pubmed-author:ArkenauH-THT, pubmed-author:DemersLL, pubmed-author:FongP CPC, pubmed-author:GualbertoAA, pubmed-author:KaravasilisVV, pubmed-author:LeitzelKK, pubmed-author:LiptonAA, pubmed-author:MolifeL RLR, pubmed-author:OlmosDD, pubmed-author:PaccagnellaLL, pubmed-author:Postel-VinaySS, pubmed-author:RaoM PMP, pubmed-author:ReidA H MAH, pubmed-author:SpicerJJ, pubmed-author:TRANQ DQD, pubmed-author:VidalLL, pubmed-author:YinDD, pubmed-author:de BonoJ SJS
pubmed:issnType	Electronic
pubmed:day	27
pubmed:volume	103
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	332-9
pubmed:dateRevised	2011-8-1
pubmed:meshHeading	pubmed-meshheading:20628389-Adult, pubmed-meshheading:20628389-Aged, pubmed-meshheading:20628389-Antibodies, Monoclonal, pubmed-meshheading:20628389-Antineoplastic Agents, pubmed-meshheading:20628389-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20628389-Cellulitis, pubmed-meshheading:20628389-Dose-Response Relationship, Drug, pubmed-meshheading:20628389-Female, pubmed-meshheading:20628389-Humans, pubmed-meshheading:20628389-Lymphopenia, pubmed-meshheading:20628389-Male, pubmed-meshheading:20628389-Middle Aged, pubmed-meshheading:20628389-Neoplasms, pubmed-meshheading:20628389-Neutropenia, pubmed-meshheading:20628389-Prostatic Neoplasms, pubmed-meshheading:20628389-Receptor, IGF Type 1, pubmed-meshheading:20628389-Taxoids
pubmed:year	2010
pubmed:articleTitle	The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
pubmed:affiliation	The Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, Sutton, Surrey, UK.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I